No Data
No Data
Form 8.5 (EPT/RI)-Renalytix Plc
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.
Renalytix AI Reduces Debt With New Share Issue
Renalytix RNLX Steno Deal; CNS Pharmaceuticals CNSP NASDAQ Compliance
H.C. Wainwright Maintains Renalytix(RNLX.US) With Buy Rating, Maintains Target Price $3
H.C. Wainwright analyst Yi Chen maintains $Renalytix(RNLX.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 27.4% and a total
Renalytix Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Renalytix Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Buy Rating Justified by Renalytix AI's European Expansion and Positive Medicare Coverage
No Data